A detailed history of Gsa Capital Partners LLP transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 58,979 shares of SBTX stock, worth $0. This represents 0.04% of its overall portfolio holdings.

Number of Shares
58,979
Previous 128,889 54.24%
Holding current value
$0
Previous $0 Infinity%
% of portfolio
0.04%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
N/A
-69,910 Reduced 54.24%
58,979 $502,000
Q1 2024

May 03, 2024

BUY
N/A
13,545 Added 11.74%
128,889 $0
Q4 2023

Feb 16, 2024

BUY
N/A
115,344 New
115,344 $0
Q1 2023

May 12, 2023

BUY
N/A
10,744 New
10,744 $0
Q2 2022

Aug 09, 2022

SELL
$2.9 - $4.44 $66,392 - $101,649
-22,894 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$3.51 - $6.74 $39,673 - $76,182
11,303 Added 97.52%
22,894 $80,000
Q4 2021

Feb 14, 2022

BUY
$6.03 - $11.67 $69,893 - $135,266
11,591 New
11,591 $77,000

Others Institutions Holding SBTX

About Silverback Therapeutics, Inc.


  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.